CLS receives strong China patent for the TRANBERG® technology and the imILT® method

Clinical Laserthermia Systems (CLS) (publ), has now an approved patent in China covering the important parts of the technology in the TRANBERG®|Thermal Therapy System and for the unique content in the company’s imILT treatment for metastatic cancer. The patent is named ”Apparatus and methods for determining a property of a tissue”, with expiration year 2027.

“CLS now has an excellent patent protection in China. We have further developed our European basic patent for immunological treatment, and thereby obtained an enhanced protection for both technology and method on the Chinese market”, said Stephan Dymling, CTO of CLS. “Except for increasing the value of our patent portfolio, this patent it an important asset when exchanging technical information with stakeholders in China”, said Stefan Dymling.

This information is such that Clinical Laserthermia Systems AB (publ) is required to publish pursuant to the EE Market Abuse Directive. The contact person arranged for the release of this information on 1 December 2017, at 11:20 AM CET.

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se